Topics

FDA approves BMS' Zeposia in relapsing #MultipleSclerosis, but #Covid19 will delay its market entry https://bit.ly/2WInSxa pic.twitter.com/6GDVNL1yhO

08:22 EDT 26 Mar 2020 | Pharmafile

FDA approves BMS' Zeposia in relapsing , but will delay its market entry https://bit.ly/2WInSxa 

Original Article: FDA approves BMS' Zeposia in relapsing #MultipleSclerosis, but #Covid19 will delay its market entry https://bit.ly/2WInSxa pic.twitter.com/6GDVNL1yhO

NEXT ARTICLE

More From BioPortfolio on "FDA approves BMS' Zeposia in relapsing #MultipleSclerosis, but #Covid19 will delay its market entry https://bit.ly/2WInSxa pic.twitter.com/6GDVNL1yhO"

Quick Search